Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Volanesorsen, Inotersen And Erenumab Nearing End Of EU Review Process

Executive Summary

Some 17 products are in the late stages of evaluation at the European Medicines Agency, including half a dozen orphans, a handful of other new drugs, and a clutch of biosimilars.

You may also be interested in...



EU CAR-T Race Tightens After Yescarta Reverts To Standard Review

Kite and Novartis are vying to be the first company to have a CAR-T therapy approved in the EU. Both companies are hoping to be able to treat patients with r/r DLBCL.

More Biosimilars Of Herceptin And Remicade Get EMA Yes

The EMA’s CHMP has adopted positive opinions on two more biosimilar products: trastuzumab and infliximab. Sixteen biosimilars remain under review at the agency.

Rare Lipid Disorder Drug To Reach Patients Faster Under UK Early Access Scheme

The UK drug regulator has granted volanesorsen a positive scientific opinion under its early access to medicines scheme for use in patients with familial chylomicronemia syndrome. The drug’s sponsor, Akcea Therapeutics, is hoping to get the drug approved in the EU, the US and Canada this year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB002268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel